We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Senate Committee Grills Azar on Eli Lilly Price Hikes
Senate Committee Grills Azar on Eli Lilly Price Hikes
Alex Azar, President Trump’s nominee for Secretary of Health and Human Services, emphasized his view that “drug prices are too high” to the Senate Finance Committee, even as Democrats continued to ask about his role in drug cost increases at Eli Lilly when he served as its president.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor